GERN Stock Risk & Deep Value Analysis
Geron Corp
DVR Score
out of 10
The Bottom Line on GERN
We analyzed Geron Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GERN through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
GERN Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Low
GERN Deep Value Analysis
GERN Red Flags & Warning Signs
- âš
Lower-than-expected commercial uptake of imetelstat in MDS due to competitive pressures or access issues
- âš
Negative or inconclusive data readout from the IMpactMF Phase 3 trial
- âš
Need for significant additional dilutive financing if cash burn exceeds revenue growth
- âš
Emergence of superior competitive therapies or new drug classes
Unlock GERN Red Flags & Risk Warnings
Create a free account to see the full analysis
GERN Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by patent protection for imetelstat and its unique mechanism of action as a first-in-class telomerase inhibitor. As market adoption increases in MDS and potentially MF, patient switching costs (due to established therapy and clinical benefit) will also contribute to durability.
GERN Competitive Moat Analysis
Sign up to see competitive advantages
GERN Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Call and Commercialization Update (Estimated early-March 2026)
- •Sales and prescription volume growth updates for imetelstat in lower-risk MDS (Q1 2026 earnings)
Medium-Term (6-18 months)
- •IMpactMF (Myelofibrosis) Phase 3 trial update and potential interim analysis readouts (H2 2026 - H1 2027)
- •Potential strategic partnerships for ex-US commercialization or pipeline expansion
Long-Term (18+ months)
- •FDA/EMA approval and commercial launch of imetelstat for Myelofibrosis (Post-2027)
- •Establishment of imetelstat as a standard of care in both MDS and MF, driving market leadership
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
GERN Bull Case: What Could Go Right
- ✓
Acceleration in imetelstat revenue growth and market share capture in MDS
- ✓
Positive clinical trial updates and data readouts for IMpactMF (Myelofibrosis)
- ✓
Improved cash flow management and clear path to profitability
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
